Pyxis Oncology, Inc. (PYXS) vs Sutro Biopharma, Inc. (STRO)
Pyxis Oncology, Inc. and Sutro Biopharma, Inc. are both Biotechnology companies. Pyxis Oncology, Inc. and Sutro Biopharma, Inc. are of similar size ($260.5M and $250.2M). Pyxis Oncology, Inc. has the higher net margin (0.00% vs −395.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Pyxis Oncology, Inc. leads on 6 and Sutro Biopharma, Inc. on 5.
Valuation
Profitability
| Metric | PYXS | STRO | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (319.57%) | 0.00% |
| Net margin | 0.00% | (395.25%) | 0.00% |
| Free cash flow margin | 0.00% | (318.63%) | 0.00% |
| Return on equity | (179.10%) | 266.76% | (57.72%) |
| Return on assets | (99.62%) | (79.08%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack